pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 30 Non-oncology: 20
Oncology: 10
Under Consideration for Negotiation 34 Non-oncology: 21
Oncology: 13
Completed Negotiations 454 With Letter of Intent: 393
Without agreement: 61
Negotiations That Were Not Pursued 85

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Riabni Amgen Canada Inc. Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Tecentriq and bevacizumab HOFFMANN-LA ROCHE LIMITED TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Venclexta AbbVie Corporation Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Zolgensma Novartis Pharmaceuticals Canada Inc. Spinal Muscular Atrophy
Calquence ASTRAZENECA CANADA INC Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Calquence ASTRAZENECA CANADA INC Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Enerzair Breezhaler Valeo Pharma Inc. Asthma
Atectura Breezhaler Valeo Pharma Inc. Asthma

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks